Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib

AIM: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). MATERIALS & METHODS: CECs in advanced HCC patients receiving sorafenib were counted...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepat Oncol
Principais autores: Giovanis, Petros, Pianezze, Graziano, Vincenzi, Valter, Manuppelli, Carla, Boaretto, Massimo, Pastorelli, Davide
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2017
Assuntos:
Clinical Trial Perspective
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095409/
https://ncbi.nlm.nih.gov/pubmed/30191052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados